COPD

During his interview, Criner discusses several notable updates to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report regarding COPD care.

In these updates and new sections, the 2025 GOLD report included highlighted climate change, cardiovascular risk, and pulmonary hypertension.

Antonio Anzueto, MD, discusses how dupilumab fits into treatment algorithms for patients with uncontrolled COPD.

Stephanie Christenson, MD, discusses the impact of recent regulatory approvals and pipeline movement for chronic obstructive pulmonary disease.

New research presented at CHEST 2024 highlights ensifentrine’s effectiveness in improving lung function, symptoms, and quality of life for COPD patients, regardless of disease severity.

This approval by the FDA follows positive findings from the pivotal BOREAS and NOTUS trials on adults with uncontrolled COPD.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

This model and its service components may be implemented in the future to allow for improvements to primary care programs, with the goal being benefits to patients with COPD.

In this summary of major news in pulmonology covered in June 2024, approvals by the FDA, new episodes of Lungcast, news on COPD, and more are highlighted.

In this HCPLive Special Report, experts review ensifentrine's role as a novel maintenance therapy for COPD.

Ensifentrine, a PDE3 and 4 inhibitor from Verona Pharma, was associated with significantly improved lung function and reduced COPD exacerbations over 24 weeks.

Clinical insights on the relationship between comorbidities in COPD and how multimorbidity plays a role in treatment decisions.

Focusing on evolving therapeutic paradigms for patients with COPD, experts discuss the importance of earlier diagnosis and treatment.

Experts share perspectives on the future treatment landscape for patients with COPD, highlighting the importance of precision medicine and the remaining unmet needs.

The panel discusses emerging treatment approaches in COPD and reviews the study design and topline results from the BOREAS trial investigating dupilumab.

These data indicate the benefits of implementing individual protective measures in winter by patients with COPD.

Igor Barjaktarevic, MD, PhD, discusses the evolving treatment landscape in COPD, highlighting current treatment approaches and novel therapies on the horizon.

Experts on respiratory diseases discuss the GOLD treatment guidelines for COPD and discuss research that is informing treatment strategies.

Focusing on the role of eosinophils in diagnosing COPD, the panel discusses how often they should be tested, the cut-off value, and the natural changes of eosinophils in the disease course.

The panel discusses unmet needs in the COPD treatment landscape, highlights the shortcomings of current treatment strategies, and provides insights on diagnostic practices.

The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

Igor Barjaktarevic, MD, PhD, provides insights on the evolving role of biomarkers in COPD, highlighting the role of eosinophils on informing treatment decisions.

1) Nicola A. Hanania, MD, MS, discusses what we have learned from asthma research on the involvement of type 2 inflammation that is applicable to COPD.

Use of dupilumab reduced exacerbations and improved lung function in COPD patients with type 2 inflammation.

The expert panel offers insights on the concept of extending phenotypes into treatable traits in patients with COPD.

Three experts on respiratory diseases give an overview of chronic obstructive pulmonary disease (COPD) and its impact on patients and the healthcare system.

This analysis indicates that quantitative interstitial abnormalities may indicate alterations in lung tissue processes that can result in short- and long-term consequences as far as symptoms.

These data highlight the benefits and drawbacks of the STAR and GOLD severity classification systems for COPD patients.

These data add to the growing body of literature on the impacts of different types of air pollution on respiratory conditions such as COPD and asthma.